This is an NIH intramural study of 40 CFS patients and controls. A 'fishing expedition'.
It is related in a sense that both Lapp and Simmaron (Dan Peterson) are advisors. Both Lapp and Peterson are proponents of ampligen for CFS as reflected in the June 5 letter by 17 biomedical and clinical experts. Francis Collins stated in December that they are considering clinical trials of both ampligen and retuximab --- so it's worth keeping an eye out. IMO, an ampligen clinical trial is up next.